GHRH analogue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-15. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
However, a 2015 estimate that used a new method for calibrating molecular clocks confirmed that while modern birds originated early in the Late Cretaceous, likely in Western Gondwana, a pulse of diversification in all major groups occurred around the Cretaceous–Palaeogene extinction event. Modern birds would have expanded from West Gondwana through two routes. One route was an Antarctic interchange in the Paleogene. The other route was probably via Paleocene land bridges between South America and North America, which allowed for the rapid expansion and diversification of Neornithes into the Holarctic and Paleotropics. On the other hand, the occurrence of Asteriornis in the Northern Hemisphere suggest that Neornithes dispersed out of East Gondwana before the Paleocene.
In November 2018, Cava Group bought Zoës Kitchen, a restaurant chain with more than 250 locations, in a deal worth $300 million, taking the company private and helping Cava expand further into the suburbs. As of August 2021, there were 133 Cava locations. All Cava restaurants are company-owned, and none are franchised. In 2020, Cava Group converted seven of its Zoës Kitchen locations to Cava-branded restaurants, with plans to convert 50 more in 2021. It has additional off-premises and digital kitchens dedicated to preparing food for online orders. As of May 2026, Cava operated 474 restaurant locations in the United States.
List of projectile attacks from Lebanon on Israel and the Golan Heights Outline of the Gaza war Palestinian insurgency in South Lebanon Hamas in Lebanon April 2023 Palestinian rocket attacks on Israel Lebanese displacement during the Israel–Hezbollah conflict (2023–present) Ali Damoush
Sources: en.wikipedia.org
In addition, the Kanji of the Year (kotoshi no kanji) has been selected since 1995, and both the kanji and the word/phrase of the year often reflect current Japanese events and attitudes. For example, in 2011, following the Fukushima nuclear disaster, the frustratingly enigmatic phrase used by Japanese officials before the explosion regarding the possibility of a meltdown - "the possibility of recriticality is not zero" (Sairinkai no kanōsei zero de wa nai) - became the top phrase of the year. In the same year, the kanji for "bond" (i.e., family ties or friendship) became the kanji of the year, expressing the importance of collectiveness in the face of disaster. Liechtenstein: Word of the year (Liechtenstein) since 2002. In Norway, the Word of the year poll has been carried out since 2012. In Portugal, the Word of the year poll has been carried out since 2009. In Russia, the Word of the year poll has been carried out since 2007. In Slovenia, the word of the year poll has been carried out since 2016. Each year, it is announced in January together with the SSL (Slovenian Sign Language) gesture of the year. In Spain, a Word of the year has been selected by Fundéu since 2013. Switzerland: Word of the year (Switzerland), since 2003. In Ukraine, the Word of the year poll has been carried out since 2013. In The Netherlands, a word of the year poll is carried out by dictionary publisher Van Dale since 2007.
The Goths were expanding towards the Lower Danube from the 230s, forcing the native peoples to flee to the Roman Empire or to accept their suzerainty. The Goths' rule ended abruptly when the Huns invaded their territory in 376, causing new waves of migrations. The Huns forced the remnants of the local population into submission, but their empire collapsed in 454. The Gepids took possession of the former Dacia province. Place names that are of Slavic origin abound in Romania, indicating that a significant Slavic-speaking population lived in the territory. The first Slavic groups settled in Moldavia and Wallachia in the 6th century, in Transylvania around 600. The nomadic Avars defeated the Gepids and established a powerful empire around 570. The Bulgars, who also came from the European Pontic steppe, occupied the Lower Danube region in 680.
=== Access to healthcare === In 2021, the French Senate's Delegation for Women's Rights reported that women's health was not considered a priority in rural areas, where medical desertification limits access to gynecological care. This can result in delayed care and inadequate cancer screening. France has faced a shortage of medical gynecologists, with some departments lacking them entirely. Medical gynecology, a discipline distinct from obstetrics and specific to France, saw a halt in specialist training from 1984 to 2003 as the country considered aligning with other European healthcare systems that do not maintain this distinction.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.